|
KMID : 0882420140870040496
|
|
Korean Journal of Medicine
2014 Volume.87 No. 4 p.496 ~ p.500
|
|
|
Azacitidine-Induced Lung Injury in a Patient with Myelodysplastic Syndrome
|
|
Kim Ho-Cheol
Kim Sang-Hyung
Ahn Ji-Hwan
Kwon Hye-Mi
Choi Jong-Han
Kim Tae-Hyung
Lee Je-Hwan
|
|
|
Abstract
|
|
|
|
In randomized phase 3 clinical trials azacitidine has been shown to prolong survival in patients with higher-risk myelodysplastic syndrome (MDS). Therefore, azacitidine therapy should be considered for treating MDS patients with higher-risk disease. A 78- year-old male was administered the first cycle of azacitidine treatment for higher-risk MDS. On day three of chemotherapy he complained of fever and dyspnea, and radiographic findings revealed bilateral perihilar-peribronchial infiltration and a small amount of pleural effusion. Considering the possibility of pneumonia, intravenous broad-spectrum antibiotics were administered and azacitidine therapy was discontinued. Upon improvement of the patient’s subjective symptoms and radiographic abnormalities, azacitidine therapy was resumed. However, fever and dyspnea developed again upon recommencement of azacitidine therapy. A diagnosis was made of azacitidine-induced lung injury and corticosteroid treatment was administered. Although lung injury is a rare complication induced by azacitidine, physicians should be aware of this life-threatening side effect.
|
|
|
KEYWORD
|
|
|
Myelodysplastic Syndrome, Azacitidine, Lung injury
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|